Quarterly report pursuant to Section 13 or 15(d)

CONCENTRATIONS

CONCENTRATIONS	3 Months Ended
Mar. 31, 2015
Notes to Financial Statements
Note 17 - CONCENTRATIONS	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. The Companys revenues earned from sale of products and services for the three months ended March 31, 2015 included 38%, 15% and 18% (aggregate of 71%) from three customers of the Companys total revenues. The Companys revenues earned from sale of products and services for the three months ended March 31, 2014 included an aggregate of 85% from one customer of the Companys total revenues. Two customers accounted for 61% and 18% of the Companys total accounts receivable at March 31, 2015 and three customers accounted for 65%, 16% and 10% of the Companys total accounts receivable at December 31, 2014. The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant.

CONCENTRATIONS

3 Months Ended

Mar. 31, 2015

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

The Companys revenues earned from sale of products and services for the three months ended March 31, 2015 included 38%, 15% and 18% (aggregate of 71%) from three customers of the Companys total revenues.

The Companys revenues earned from sale of products and services for the three months ended March 31, 2014 included an aggregate of 85% from one customer of the Companys total revenues.

Two customers accounted for 61% and 18% of the Companys total accounts receivable at March 31, 2015 and three customers accounted for 65%, 16% and 10% of the Companys total accounts receivable at December 31, 2014.

The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References + Details